surpass et: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
Published 2 years ago • 1.1K plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:28
surpass et: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
-
1:57
surpass et: p1101 in essential thrombocythemia
-
1:46
current treatment approaches in et and an insight into the surpass-et trial
-
2:05
the surpass-et study: evaluating novel treatment approaches in et
-
1:24
exceed-et: ropeginterferon alfa-2b in adults with essential thrombocythemia
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
2:15
advances in the risk stratification and treatment of essential thrombocythemia
-
5:21
challenges in the treatment and management of et and the need to improve therapeutic approaches
-
26:51
ascp | mls | mlt | essential thrombocythemia | myeloproliferative neoplasms
-
9:35
what is essential thrombocythemia?
-
2:01:47
conversation with mpn specialists: focus on essential thrombocythemia
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
0:56
rop-et: a phase iii non-randomized study of ropeginterferon alfa-2b in patients with et
-
0:59
matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2l treatment of r/r lbcl
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
2:41
an overview of the latest advances in hematology
-
1:17
what are the biggest challenges currently facing haematology?
-
1:34
are thrombotic risk and progression in et predictable?
-
0:52
insights from advance iv study: efgartigimod increases platelet counts of patients with itp
-
8:07
essential thrombocythemia: outcomes, unmet needs, and therapeutic strategies